Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo	258
Overall Study	STARTED	Sotagliflozin 200 mg	261
Overall Study	STARTED	Sotagliflozin 400 mg	263
Overall Study	Completed the 24 Week Treatment Period	Placebo	236
Overall Study	Completed the 24 Week Treatment Period	Sotagliflozin 200 mg	239
Overall Study	Completed the 24 Week Treatment Period	Sotagliflozin 400 mg	240
Overall Study	COMPLETED	Placebo	225
Overall Study	COMPLETED	Sotagliflozin 200 mg	226
Overall Study	COMPLETED	Sotagliflozin 400 mg	227
Overall Study	NOT COMPLETED	Placebo	33
Overall Study	NOT COMPLETED	Sotagliflozin 200 mg	35
Overall Study	NOT COMPLETED	Sotagliflozin 400 mg	36

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02421510/flow